PerkinElmer has inked a definitive agreement to purchase drug discovery and life sciences product developer Caliper Life Sciences for approximately $600 million in cash.
PerkinElmer said that acquisition of Caliper will enhance its position in molecular imaging and detection for human and environmental health. The companies have agreed on a purchase price of $10.50 per share, a 42% premium over Caliper's closing price of $7.39 per share on September 7.
The deal is expected to be completed in the fourth quarter of 2011, subject to customary closing conditions, including approval of Caliper stockholders and the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
